Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04702958 · ClinicalTrials.gov registry record
TRANSFORM-HF Ancillary Mechanistic Study
A clinical trial, sponsored by Inova Health Care Services.
- Completed
- Registry status
- 150
- Enrollment target
NCT04702958: Completed study, sponsored by Inova Health Care Services.
NCT04702958 is a clinical trial that has completed, run by Inova Health Care Services. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04702958 has completed, sponsored by Inova Health Care Services.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
Patients with heart failure are frequently treated with diuretics, including furosemide and torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is studying if torsemide is superior than furosemide for reducing the endpoint of death or hospitalization, but is not designed to study why. This ancillary study seeks to measure proteins in the blood and urine to help explain the underlying mechanism for why patients who take one of these diuretics may have better outcomes than patients who take the other.
Primary Outcome
How the biomarkers are different between groups
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-12-10 |
| Est. Completion | 2023-05-30 |
What the finished NCT04702958 record still lists
NCT04702958 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04702958 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04702958 about?
NCT04702958 is a clinical study titled "TRANSFORM-HF Ancillary Mechanistic Study". Patients with heart failure are frequently treated with diuretics, including furosemide and torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is studying if torsemide is superior than furosemide for reducing the endpoint of death or hospitalization, but is not de...
What is the current status of trial NCT04702958?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2020-12-10. Estimated completion is 2023-05-30.
Who is sponsoring clinical trial NCT04702958?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI